Chandani M. Patel

Chandani M. Patel

Auto-generated profile, based on publicly available information

Chandani M. Patel

Department of Pharmacology and Regenerative Medicine, University of Illinois Chicago, Chicago, IL

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2025 in Blood
Verified
Journal Article
Closed access
Sen ZhangSen Zhang
Sen Zhang
CACharles E. Ayemoba
Charles E. Ayemoba
ASAnna M. Di Staulo
Anna M. Di Staulo
KJKenneth Joves
Kenneth Joves
CPChandani M. Patel
Chandani M. Patel
SPSandra Pinho
Sandra Pinho
Hematopoietic stem cells (HSCs) responsible for blood cell production and their bone marrow regulatory niches undergo age-related changes, affecting immune responses and predisposing individuals to hematologic malignancies. Here, we show that the age-related alterations of the megakaryocytic niche and associated downregulation of platelet factor 4 (PF4) are pivotal mechanisms driving HSC aging. PF4-deficient mice display several phenotypes reminiscent of accelerated HSC aging, including lymphopenia, increased myeloid output, and DNA damage, mimicking physiologically aged HSCs. Remarkably, recombinant PF4 administration restored old HSCs to youthful functional phenotypes characterized by improved cell polarity, reduced DNA damage, enhanced in vivo reconstitution capacity, and balanced lineage output. Mechanistically, we identified low-density lipoprotein receptor and C-X-C motif chemokine receptor 3 as HSC receptors transmitting the PF4 signal, with double knockout mice exhibiting exacerbated HSC aging phenotypes similar to PF4-deficient mice. Furthermore, human HSCs across various age groups also respond to the youthful PF4 signaling, highlighting its potential for rejuvenating aged hematopoietic systems. These findings pave the way for targeted therapies aimed at reversing age-related HSC decline, with potential implications in the prevention or improvement of the course of age-related hematopoietic diseases.

13 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAmélie Collins
Amélie Collins
JSJames W. Swann
James W. Swann
MPMelissa A. Proven
Melissa A. Proven
CPChandani M. Patel
Chandani M. Patel
CMCarl A. Mitchell
Carl A. Mitchell
EPEmmanuelle Passegué
Emmanuelle Passegué
SUMMARY: Neonates, in contrast to adults, are highly susceptible to inflammation and infection. Here we investigate how late fetal liver (FL) mouse hematopoietic stem and progenitor cells (HSPC) respond to inflammation, testing the hypothesis that deficits in engagement of emergency myelopoiesis (EM) pathways limit neutrophil output and contribute to perinatal neutropenia. We show that despite similar molecular wiring as adults, fetal HSPCs have limited production of myeloid cells at steady state and fail to activate a classical EM transcriptional program. Moreover, we find that fetal HSPCs are capable of responding to EM-inducing inflammatory stimuli in vitro , but are restricted by maternal anti-inflammatory factors, primarily interleukin-10 (IL-10), from activating EM pathways in utero . Accordingly, we demonstrate that loss of maternal IL-10 restores EM activation in fetal HSPCs but at the cost of premature parturition. These results reveal the evolutionary trade-off inherent in maternal anti-inflammatory responses that maintain pregnancy but render the fetus unresponsive to EM activation signals and susceptible to infection. HIGHLIGHTS: The structure of the HSPC compartment is conserved from late fetal to adult life. Fetal HSPCs have diminished steady-state myeloid cell production compared to adult. Fetal HSPCs are restricted from engaging in emergency myelopoiesis by maternal IL-10. Restriction of emergency myelopoiesis may explain neutropenia in septic neonates. eTOC BLURB: Fetal hematopoietic stem and progenitor cells are restricted from activating emergency myelopoiesis pathways by maternal IL-10, resulting in inadequate myeloid cell production in response to inflammatory challenges and contributing to neonatal neutropenia.